Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Synthesis and In Vitro Properties of Prednisolone 21-Sulfate Sodium as a Colon-Specific Prodrug of Prednisolone

  • Doh, Min-Ju (College of Pharmacy, Pusan National University) ;
  • Jung, Yun-Jin (College of Pharmacy, Pusan National University) ;
  • Kim, In-ho (College of Pharmacy, Pusan National University) ;
  • Kong, Hye-Sik (College of Pharmacy, Pusan National University) ;
  • Kim, Young-Mi (College of Pharmacy, Pusan National University)
  • Published : 2003.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

Colon-specific delivery of glucocorticoids is highly desirable for the efficient treatment of inflammatory bowel disease. We synthesized prednisolone 21-sulfate sodium (PDS) as a colon-specific prodrug of prednisolone (PD) and investigated its properties using rats as test animals. We expected that introduction of sulfate ester as a sodium salt might increase the hydrophilicity and restrict the absorption in the GI tract. If PDS is stable and nonabsorbable in the upper intestine, it will be delivered to the colon as an intact form, where it hydrolyze by the sulfatase to release PD. Compared with PD, the solubility of PDS increased and the apparent partition coefficient decreased greatly. PDS was stable on incubation with pH 1.2 and 6.8 buffer solutions and with the contents of the stomach and small intestine. On incubation with the cecal contents, PDS decreased to 9.6％ of the dose in 10 h producing PD. The amount of PD increased to give a maximum 54％ of the dose and decreased. As a control, when PD was incubated with the cecal contents, it decreased to 29％ of the dose in 8 h, which implied that reduction of PD proceeded under such conditions. These results suggested that hydrolysis of PDS took place to produce and accumulate PD, which decreased by reduction as the incubation period extended. Our results suggested that PDS can be a promising colon-specific prodrug of PD, and sulfate ester group might serve as a potential colon-specific promoiety, especially for the drugs which are resistant to reduction in the colon.

Keywords

References

  1. Brown, J. P., McGarraugh, G. V., Parkinson, T. M., Wingard, R. E., and Onderdonk, A. B., A polymeric drug for treatment of inflammatory bowel disease. J. Med. Chem., 26, 1300-1307 (1983) https://doi.org/10.1021/jm00363a015
  2. Crotty, B. and Jewel, J. P., Drug therapy of ulcerative colitis. Br. J. Clin. Pharmaco., 34, 189-198 (1992) https://doi.org/10.1111/j.1365-2125.1992.tb04124.x
  3. Faigle, J. W., Drug metabolism in the colon wall and lumen. In: Bieck P. R. (ed), Colonic drug absorption and metabolism. New York, NY: Marcel Dekker Inc. pp 29-54 (1993)
  4. Fedorak, R. N., Haeberlin, B., Empey, L. R., Cui, N., Nolen, H. $3^{rd}$, Jewell, L. D., and Friend, D. R., Colonic delivery of dexamethasone from a prodrug accelerates healing of colitis in rats without adrenal suppression. Gastroenterology., 108, 1688-1699 (1995) https://doi.org/10.1016/0016-5085(95)90130-2
  5. Friedman, S. and Blumberg, R. S., Inflammatory bowel disease. In: Harrisons principles of internal medicine, 15th edn. CD-ROM, New York: McGraw-Hill (2001)
  6. Friend, D. R. and Chang, G. W., A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. J. Med. Chem., 27, 261-266 (1984) https://doi.org/10.1021/jm00369a005
  7. Friend, D. R. and Chang, G. W., Drug glycosides: Potential prodrugs for colon-specific drug delivery. J. Med. Chem., 28, 51-57 (1985) https://doi.org/10.1021/jm00379a012
  8. Huijghebaert, S., Sim, S. M., Back, D. J., and Eyssen, H. J., Distribution of estrone sulfatase activity in the intestine of germ-free and conventional rats. Steroid Biochem., 20, 1175-1179 (1984) https://doi.org/10.1016/0022-4731(84)90363-7
  9. Istran, C., Gabor, S., and Ferene, S., Glycosides of 5-amino-salicylic acid. Magy. Kem. FOLY., 97, 143-147 (1991)
  10. Jung, Y. J., Lee, J. S., and Kim Y. M., Synthesis and in vitrolin vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid. J. Pharm. Sci., 89, 594-602 (2000) https://doi.org/10.1002/(SICI)1520-6017(200005)89:5<594::AID-JPS5>3.0.CO;2-8
  11. Jung, Y. J., Lee, J. S., and Kim, Y. M., Colon-specific prodrug of 5-aminosalicylic acid: Synthesis and in vitrolin vivo properties of acidic amino acid derivatives of 5-aminosalicylic acid. J. Pharm. Sci., 90, 1767-1775 (2001) https://doi.org/10.1002/jps.1126
  12. Kopeckova, P. and Kopecek, J., Release of 5-aminosalicylic acid from bioadhesive N-(2-hydroxypropyl) methacrylamide copolymers by azoreductases in vitro. Makromol. Chem., 191, 2037-2045 (1990) https://doi.org/10.1002/macp.1990.021910906
  13. Larsen, C. and Johansen, M., Dextrans as carriers for drug compounds-realized and potential applications. Arch. Pharm. Chemi., 92, 809-830 (1985)
  14. Mallett, A. K., Rowland, I. R., and Bearne, C. A., Influence of wheat bran on some reductive and hydrolytic activity of rat cecal flora. Nutrition and Cancer, 8, 125-131 (1986) https://doi.org/10.1080/01635588609513885
  15. McLeod, A. D., Friend, D. R., and Tozer, T. N., Glucocorticoid-dextran conjugate as potential prodrugs for colon-specific delivery: Hydrolysis in rat gastrointestinal tract contents. J. Pharm. Sci., 83, 1284-1288 (1994) https://doi.org/10.1002/jps.2600830919
  16. McLeod, A. D., Friend, D. R., and Tozer, T. N., Synthesis and chemical stability of glucocorticoid-dextran ester: potential prodrugs for colon-specific delivery. Int. J. Pharm., 92, 105-114 (1993) https://doi.org/10.1016/0378-5173(93)90269-L
  17. Nakamura, J., Haraguchi, Y., Sasaki, H., and Shibasaki, J., Effect of fasting on the hydrolysis of salicyluric acid in rabbit intestinal microorganisms. J. Pharmacobiodyn., 12, 602-607 (1989) https://doi.org/10.1248/bpb1978.12.602
  18. Rubinstein, A., Microbially controlled drug delivery to the colon. Biopharm & Drug Disposition, 11, 465-475 (1990) https://doi.org/10.1002/bdd.2510110602
  19. Ryde, E. M., Low-molecular-weight azo compounds. In: Friend D. R. (Ed), Oral colon specific drug delivery. CRC press, Boca Raton, FL. Pp. 143-152, (1992)
  20. Schimmer, B. P. and Parker, K. L., Adrenocorticotropic Hormone; Adrenocortical steroids and their synthetic analogs; Inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman, J. G., Limbird, L. E., (Editors-in-chief) Goodman and Gilman's The pharmacological basis of therapeutics, 10th Ed. McGrow-Hill, New York, N.Y. pp. 1649-1677 (2001)
  21. Schwenk, M., Frank, B., Bolt, H. M., and Winne, D., Intestinal first-pass effects of estrone sulfate and estrone in the rat. Arzneimittelforschung., 31, 1254-1257 (1982)
  22. Shiau, S. Y. and Chang, G., Effect of dietary fiber on fecal mucinase and beta-glucuronidase activity in rats. J. Nutrition., 13, 138-144 (1983)
  23. Van Eldere, J., Robben, J., De Pauw, G., Merckx, R., and Eyssen, H., Isolation and identification of intestinal steroid-desulfating bacteria from rats and humans. Appl. Evirn. Microbiol., 54, 2112-2117 (1994)